Medicus Pharma Ltd. Common Stock (MDCX)
Automate Your Wheel Strategy on MDCX
With Tiblio's Option Bot, you can configure your own wheel strategy including MDCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDCX
- Rev/Share 0.0
- Book/Share -0.0432
- PB -36.8487
- Debt/Equity -0.2596
- CurrentRatio 0.9178
- ROIC 53.6369
- MktCap 39673699.0
- FreeCF/Share -1.0431
- PFCF -2.0414
- PE -2.4745
- Debt/Assets 0.0237
- DivYield 0
- ROE -7.1137
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Published: March 06, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
Read More
Medicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-end
Published: February 14, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) has announced progress in its Phase 2 clinical study SKNJCT-003, which is evaluating its investigational drug D-MNA in basal cell carcinoma (BCC). The company said that the trial, currently underway at nine clinical sites in the United States, has now randomized more than 50% of the 60 patients expected to be enrolled.
Read More
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Published: February 14, 2025 by: Newsfile Corp
Sentiment: Neutral
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.
Read More
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA) The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA)
Read More
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Published: February 11, 2025 by: Newsfile Corp
Sentiment: Neutral
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd.
Read More
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market
Read More
About Medicus Pharma Ltd. Common Stock (MDCX)
- IPO Date 2024-11-15
- Website https://medicuspharma.com
- Industry Biotechnology
- CEO Raza Bokhari
- Employees 12